-
13 June 2025 23:10:59
- Source: Sharecast
13 June 2025
IXICO PLC
("IXICO" or the "Company")
Share Option Award & Director Bed & ISA Dealings
PDMR Dealing
Share Option Award:
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neurosciences, today announces that it has issued a total of 850,000 options to subscribe for ordinary shares of 1 pence each in the Company (the "Share Options") to Mark Austin, Chief Technology Officer, James Chandler, Chief Business Officer and Terry Reilly, VP Global Business Development. Mark Austin and James Chandler are considered Persons Discharging Managerial Responsibility under the Market Abuse Regulation (PDMRs) of the Company.
The Share Options have vesting criteria aligned with retention and annual share price growth over 3 years. The options have an exercise price equivalent to the closing share price on the date of award except for those awarded to PDMRs which have an exercise price of £0.01. All options will be subject to a hold period to the third anniversary of their award.
The achievement of share price growth each year shall be measured by calculating the 3-month average share price immediately prior to each anniversary of the option award. The growth performance can be met in full by an absolute annual compound share price growth of 40% over the three-year period or in part by a 40% share price growth as compared to the prior year. In the first year this shall be compared to a baseline price equivalent to the three-month average share price immediately prior to 1 June 2025.
Director Bed & ISA Dealings:
In addition, the Company announces that it received notification on 12 June 2025, that Grant Nash, CFO/COO and PDMR, sold 45,263 ordinary shares of 1p each in the Company and repurchased 45,263 ordinary shares into Mr Nash's ISA account. Following this transaction Mr Nash's beneficial interest in the Company's shares has not changed.
The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.
For further information please contact:
|
IXICO plc |
+44 (0) 20 3763 7499 |
|
Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer (IR) |
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated adviser and sole broker) |
+44 (0) 20 7220 0500 |
|
Giles Balleny (Corporate Finance) |
|
|
Nigel Birks (Life Sciences Specialist Sales) |
|
|
Harriet Ward (Corporate Broking) |
|
|
Michael F Johnson (Sales) |
|
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on X (formerly Twitter) @IXICOnews
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Mark Austin |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Technology Officer and PDMR |
|||
|
b)
|
Initial notification /Amendment
|
Initial |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
IXICO plc |
|||
|
b)
|
LEI
|
2138005M1F59O6HWSA97 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares in IXICO plc
|
|||
|
|
|
||||
|
Identification code |
ISIN: GB00BFXR4C20 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of Share Options |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1 pence |
350,000 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
|
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
12 June 2025 |
|||
|
f)
|
Place of the transaction
|
Off Market Transaction |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
James Chandler |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Business Officer and PDMR |
|||
|
b)
|
Initial notification /Amendment
|
Initial |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
IXICO plc |
|||
|
b)
|
LEI
|
2138005M1F59O6HWSA97 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares in IXICO plc
|
|||
|
|
|
||||
|
Identification code |
ISIN: GB00BFXR4C20 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Grant of Share Options |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1 pence |
350,000 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
|
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
12 June 2025 |
|||
|
f)
|
Place of the transaction
|
Off Market Transaction |
|||
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Grant Nash |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Financial Officer and PDMR |
|||
|
b)
|
Initial notification /Amendment
|
Initial |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
IXICO plc |
|||
|
b)
|
LEI
|
2138005M1F59O6HWSA97 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares in IXICO plc
|
|||
|
|
|
||||
|
Identification code |
ISIN: GB00BFXR4C20 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Sale and purchase of ordinary shares |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
Sale at 13.00p |
45,263 |
|
|
|
|
|
Purchase at 13.04p |
45,263 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
|
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction |
12 June 2025 |
|||
|
f) |
Place of the transaction
|
Off Market Transaction |
|||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.